BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Saniona, Boehringer Ingelheim enter $101M ion channel discovery pact in schizophrenia
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Saniona, Boehringer Ingelheim enter $101M ion channel discovery pact in schizophrenia
Aug. 30, 2016
By
Cormac Sheridan
No Comments
DUBLIN – Shares in Saniona AB gained 25 percent Monday on news of an ion channel drug discovery pact in schizophrenia with Boehringer Ingelheim GmbH worth up to €90 million (US$101 million) in up-front and milestone payments.
BioWorld